Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis.
Yoshihito UchidaMie InaoShohei TsujiHayato UemuraJun-Ichi KouyamaKayoko NaikiKayoko SugawaraMasamitsu NakaoNobuaki NakayamaYukinori ImaiTomoaki TomiyaSatoshi MochidaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
Furosemide given at baseline contributed to an unfavorable outcome in patients receiving tolvaptan; consequently, tolvaptan should be given before increasing the furosemide dose.